Pharma Mar (PHMMF) Receives Consensus Rating of “Strong Buy” from Analysts
Shares of Pharma Mar (NASDAQ:PHMMF) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Zacks has also assigned Pharma Mar an industry rank of 166 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut Pharma Mar from a “hold” rating to a “sell” rating in a research report on Friday, March 3rd.
Shares of Pharma Mar (NASDAQ PHMMF) traded up 3.69% during midday trading on Monday, reaching $4.50. The company’s stock had a trading volume of 17,895 shares. The stock’s 50-day moving average is $4.35 and its 200 day moving average is $3.37. Pharma Mar has a 12 month low of $2.13 and a 12 month high of $4.80. The stock’s market capitalization is $994.47 million.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/06/19/pharma-mar-phmmf-receives-consensus-rating-of-strong-buy-from-analysts.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.